Table 1.
Characteristics of included systematic reviews
| Source | Type of study | Includes AF-studies N |
AF-patients N |
Mean age in years | Intervention | Comparator | mean Follow-Up in years | Relevant outcomes | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AS | IS | HS | M | MB | IB | GB | MI | ||||||||
| Adam et al. 2012 [31] | MA | 3 | 50,578 | >70 | NOACs (dabigatran, apixaban, rivaroxaban) | Warfarin | ≈ 2 | X | X | X | |||||
| Agarwal et al. 2012 [27] | MA | 8 | 32,053 | 70–81.5 subgroup ≥75 |
Warfarin | Other thrombophylaxis (Aspirin, Aspirin + clopidogrel, Ximelagatran, Dabigatran, Rivaroxaban, Apixaban, Indraparinux) | 1.74a | X | |||||||
| Aguilar et al. 2005 [34] | CR + MA | 5 | 2313 | 69 | Warfarin | Placebo/control | 1.5 | X | X | X | X | X | X | ||
| Aguilar et al. 2007 [44] | MA | 8 | 9598 | 71 | Warfarin, acenocumarol | PAI (ASA, ASA + clopidogrel, triflusal) | 1.9 | X | X | X | X | X | X | ||
| Andersen et al. 2008 [37] | MA | 15 | 16,058 | 63.3–81.5 | warfarin | Placebo, antiplatelets, low dose warfarin, low-dose warfarin + aspirin | 1.7 | X | |||||||
| Assiri et al. 2013 [42] | MTM | 21 | 80,906 | 71 | Pair-wise comparison of aspirin, aspirin + clopidogrel, warfarin, apixaban, dabigatran, edoxaban, rivaroxaban and placebo | 1.85a | X | X | X | X | |||||
| Baker et al. 2012 [53] | MA | 4 | 44,733 | 69–73 | NOACs (dabigatran, apixaban, rivaroxaban) | Warfarin indirect comparison of NOACs | 1.8–2.0 | X | X | X | X | X | X | ||
| Briceno 2015 [29] | MA | 7 | 73,978 | 70–74 | NOACs (dabigatran, rivaroxaban, apixaban, edoxaban) DEVICE (Watchman left atrial occlusion device) |
Warfarin | 1–2.8 | X | X | X | |||||
| Cameron et al. 2014 [46] | MTM | 16 | 82,314 | 62–83 | VKA | NOACs ASA |
12 weeks −3.5 years | X | X | ||||||
| Capodanno et al. 2013 [47] | MA | 3 | 50,578 | 71.3 | NOACs (dabigatran, apixaban, rivaroxaban) | Warfarin | 1.9 | X | X | X | X | X | X | X | X |
| Chatterje et al. 2013 [63] | MA, MTM | 6 | 57,491 | 69.3–73 | NOACs (dabigatran, apixaban, rivaroxaban) | Warfarin, ASA | 0.23–2.0 | X | |||||||
| Coleman et al. 2012 [35] | MA | 16 | 42,983 | 69.5 | Pair-wise comparisons of warfarin (adjusted + low dose), PAI, ximelagatran, dabigatran, placebo/control | 2 | X | ||||||||
| Cooper et al. 2006 [41] | MTM | 19 | 17,833 | 68.3 | Pair-wise comparison of warfarin (adjusted + low dose), ASA, indobufen, ximelagtran, placebo/control | 1.8 | X | X | |||||||
| Dogliotti et al. 2013 [48] | MA | 5 | 51,895 | 71.4 | NOACs (dabigatran, apixaban, rivaroxaban, ximelagatran) | Warfarin | 1.75 | X | X | X | X | X | |||
| Dogliotti et al. 2014 [40] | MTM | 20 | 79,808 | 68.2 | Pair-wise comparison of ASA, ASA plus clopidogrel, VKA, dabigatran, rivaroxaban, apixaban or placebo/control | >1 | X | X | X | X | |||||
| Harenberg et al. 2012 [70] | MTM | 3 | 50,578 | 70–73 | NOACs (dabigatran, apixaban, rivaroxaban) | Warfarin | 1.88 | X | X | X | X | X | |||
| Hart et al. 1999 [4] | MA | 6 | 9874 | 70 | Adjusted-dose warfarin, PAI | Other Antithrombotic regimens placebo ASA |
Mean FU 1.7 y1.7ears, ranged from 1.2 to 2.3 | X | X | X | X | X | |||
| Hart et al. 2007 [39] | MA | 29 | 28,044 | 71 | Adjusted-dose warfarin, | PAI Placebo/No Treatment |
1.5 | X | X | X | X | X | |||
| Holster 2013 [33] | MA | 8 | 151,578 | 65–73 | NOACs (apixaban, edoxaban, rivaroxaban, dabigatran) | Warfarin | 12 weeks – 2 years | X | X | ||||||
| Jia 2014 [54] | MA | 5 | 72,961 | 70–73 | NOACs (apixaban, edoxaban, rivaroxaban, dabigatran) | Warfarin | 1.6–2.8 | X | X | X | X | X | X | X | X |
| Lega 2014 [30] | MA | 3 | 50,578 | 70–73 | NOACs (apixaban,rivaroxaban, dabigatran) | Warfarin | 1.8–2 | X | X | ||||||
| Liew et al. 2014 [49] | MA | 4 | 71,683 | no mean | NOACs (dabigatran, apixaban, rivaroxaban, edoxaban) | Warfarin | 1.8–2.8 | X | X | ||||||
| Lin 2015 [43] | MTM | 49 | 897,748 | 71 | Warfarin | ASA, dabigatran, rivaroxaban, apixaban, edoxaban, no treatment | 12 weeks −3.6 years | X | X | X | X | X | X | ||
| Lip et al. 2006 [36] | MA | 13 | 14,423 | 68.4 | Adjusted-dose warfarin | ASA fixed low-dose warfarin, placebo, ximelagatran |
2.13 | X | X | X | |||||
| Miller et al. 2012 [50] | MA | 3 | 44,563 | 71.5 | NOACs (dabigatran, apixaban, rivaroxaban) | Warfarin | 1.91 | X | X | X | X | X | X | X | X |
| Providência et al. 2014 [51] | MA | 7 | 80,290 | 71.3 | NOACs (dabigatran, apixaban, rivaroxaban, ximelagatran, edoxaban) | Warfarin | 1.96 | X | X | X | X | X | X | X | |
| Rong 2015 [66] | MA | 4 | 71,683 | 70–73 | NOACs (apixaban, edoxaban, rivaroxaban, dabigatran) | Warfarin | 1.8–2.8 | X | X | X | |||||
| Roskell et al. 2010 [67] | MTM | 26 | not stated | 71.2 | dabigatran | Indirect comparison: Placebo, ASA, ASA + clopidgrel, adj. Dose VKA | 1.87 | X | X | X | X | X | X | ||
| Ruff et al. 2014 [87] | MA | 4 | 71,683 | 71.4 | NOACs (dabigatran, apixaban, rivaroxaban, edoxaban) | Warfarin | 2 | X | X | X | X | X | X | X | X |
| Sardar et al. 2013 [64] | MA | 3 | 50,578 | 70.6 | NOACs (dabigatran, apixaban, rivaroxaban) | Warfarin | 1.88 | X | X | X | X | X | X | - | |
| Sardar et al. 2014 [32] | MA | 4 | 11,562 | subgroup for ≥75 | NOACs (dabigatran, apixaban, rivaroxaban) | Warfarin, ASA | 1.1–2.0 | X | X | ||||||
| Schneeweiss et al. 2012 [69] | MTM | 3 | 44,535 | 70–73 | NOACs (dabigatran, apixaban, rivaroxaban) | Warfarin | 1.8–2.0 | X | X | ||||||
| Segal et al. 2000 [38] | MA | 11 | 8690 | 66–80 | VKA | ASA ASA + low dose warfarin placebo |
0.3–2.6 | X | X | X | |||||
| Senoo 2015 [65] | MA | 3 | 1940 | 70–73 | NOAC (rivaroxaban, apixaban, dabigatran) | Warfarin | 1.3–2.0 | X | X | X | X | ||||
| Sharma et al. 2015 [26] (Subgroup >75 with AF) |
MA | 5 | 27,622 | >75 | Single NOACs (dabigatran, apixaban, rivaroxaban, edoxaban) | Warfarin | 1.75 | X | X | ||||||
| Taylor et al. 2001 [45] | 5 | 3298 | 73 | Warfarin | PAI | 2.35 | X | X | X | X | |||||
| Testa et al. 2012 [52] | MA | 3 | 50,578 | 71.5 | NOACs (dabigatran, apixaban, rivaroxaban) | Warfarin | >1 | X | X | X | X | X | X | ||
| Verdecchia et al. 2015 [68] | MTM | 4 | 71,683 | 71.5 | Indirect comparison (dabigatran, apixaban, rivaroxaban, edoxaban) | Dose-adjusted warfarin | 2.15 | X | X | X | X | X | X | X | |
AS All stroke, CR Cochrane Review, GB Gastrointestinal Bleeding, HS Haemorrhagic Stroke, IB Intracranial Bleeding, IS Ischemic stroke, M Mortality, MA Meta-analysis, MB Major Bleeding, MI Myocardial infarction, MA Meta-analysis, NMA network meta-analysis
a Calculated by the review team